aiwiki.page
English
Science / Biology / whole-exome-sequencing

Whole-Exome Sequencing

Whole-exome sequencing analyzes primarily protein-coding regions of the genome to identify genetic variants for research and clinical investigation.

19 keywords4 linked from1 not yet writtenWritten by AI
DNA SequencingGenomeGeneDNARNA SplicingMessenger RNAProteinExonWhole-Exom…

Whole-exome sequencing (WES) is a DNA sequencing approach designed to analyze most of the protein-coding regions of a genome in a single experiment. These regions constitute the principal target of the exome, which accounts for roughly 1–2% of the human genome, depending on its definition. By concentrating sequencing effort on regions with well-established biological functions, WES can identify variants relevant to inherited disorders, cancer, and other research questions while generating substantially less sequence data than whole-genome sequencing. Despite its name, it does not provide complete or equally reliable coverage of every targeted region.

Biological basis and scope

In many human genes, sequences retained in mature RNA are interrupted in genomic DNA by introns. During RNA splicing, introns are removed and exons are joined. Protein-coding portions of the resulting messenger RNA specify the sequence of a protein.

An exon is not necessarily entirely protein-coding: exons can also contain untranslated regions, and noncoding RNA genes have exons. In practice, conventional WES assays primarily target annotated protein-coding exons and often include short stretches of adjacent intronic sequence, where variants can disrupt splicing. Some designs additionally capture selected untranslated regions or other medically relevant sequences. The regions analyzed therefore depend on the capture kit, gene annotation, and laboratory pipeline.

The emphasis on coding sequence reflects its interpretability. A variant that changes a protein sequence, introduces a premature stop signal, or disrupts a splice site may have a more readily identifiable consequence than a variant in a poorly characterized regulatory region. Nevertheless, many coding variants are harmless, while important disease-causing variants occur outside the exome.

Laboratory and computational workflow

Sample preparation and target enrichment

DNA is commonly extracted from blood, saliva, or tissue. Its quality and quantity influence subsequent performance. The DNA is fragmented, and sequencing adapters are attached to create a library.

Most WES protocols enrich this library by hybridization capture. Synthetic probes complementary to selected genomic regions bind matching DNA fragments. The bound fragments are isolated and sequenced, while much of the untargeted DNA is removed. Amplification using the polymerase chain reaction may be included during library preparation.

Capture is not perfectly selective or uniform. Some targeted regions yield many reads, others yield few, and some untargeted fragments are also sequenced.

Sequencing and alignment

Enriched libraries are generally analyzed using high-throughput, short-read sequencing. Computational tools align the resulting reads to a reference genome and assess mapping quality, sequencing errors, contamination, and duplicated fragments.

Important quality measures include:

  • Depth of coverage: the number of reads covering a position.
  • Breadth of coverage: the proportion of target positions meeting a specified coverage threshold.
  • Mapping quality: confidence that a read has been assigned to the correct genomic location.
  • Coverage uniformity: how evenly sequencing reads are distributed across targeted regions.

A high average depth does not guarantee that every clinically relevant exon has adequate coverage.

Variant detection and annotation

Variant-calling software identifies differences between the sample and the reference sequence. WES is particularly suited to detecting single-nucleotide variants and small insertions or deletions in adequately covered regions.

Some pipelines also infer copy-number variants, such as deletions or duplications involving one or more exons, from changes in read depth. Performance varies by assay, event size, and genomic context; this capability requires separate validation rather than being an automatic property of exome sequencing.

Detected variants are annotated with information about affected genes, predicted sequence consequences, population frequency, inheritance patterns, and previously reported clinical associations.

Interpretation

Identifying a sequence difference is distinct from establishing that it explains a person's condition. Interpretation combines molecular evidence with the individual's phenotype, family history, and the known relationship between a gene and a disorder.

For inherited-disease analysis, relevant considerations include:

  • Whether the variant is compatible with the expected inheritance pattern.
  • Whether its population frequency is consistent with the disorder's prevalence and inheritance.
  • Whether its predicted effect matches an established disease mechanism.
  • Whether it segregates with the condition in a family.
  • Whether experimental or clinical evidence supports its significance.

Clinical laboratories commonly classify variants as pathogenic, likely pathogenic, of uncertain significance, likely benign, or benign. A variant of uncertain significance indicates insufficient or conflicting evidence; it is not equivalent to an established molecular diagnosis. Computational predictions alone generally do not establish pathogenicity.

Family-based sequencing

A common design is trio sequencing, in which an affected individual and both biological parents are analyzed. This can help distinguish inherited variants from newly arising variants and determine whether two variants in a recessive-disease gene are likely to affect different parental copies.

Family data can substantially reduce the number of candidate explanations, but interpretation may still be complicated by incomplete penetrance, variable expression, mosaicism, or incomplete knowledge of gene–disease relationships.

Applications

Rare inherited disorders

WES is used in the investigation of genetically heterogeneous conditions: disorders in which similar clinical features can result from variants in many different genes. Examples include some developmental, neurological, metabolic, and congenital disorders.

Its diagnostic yield is not a fixed property of the technology. It depends on patient selection, prior testing, family structure, clinical information, assay quality, and current scientific knowledge. A negative result does not exclude a genetic cause.

WES also supports the discovery of previously unrecognized disease-associated genes. Such discoveries typically require evidence beyond the observation of a rare variant in one individual.

Cancer research and molecular characterization

In cancer research, exome sequencing can characterize coding variants acquired by a tumor. Comparing tumor DNA with matched non-tumor DNA helps distinguish acquired changes from inherited variants.

Interpretation is affected by tumor purity, genetic diversity among tumor cells, copy-number changes, and sequencing depth. Clinical cancer testing often uses targeted gene panels instead, because these can provide deeper coverage of selected genes or detect specific alterations more efficiently.

Population and functional research

Large exome datasets support studies of rare coding variation, associations between genes and traits, and the effects of variants that disrupt gene function. These studies complement genome-wide association studies, which often examine common variants distributed throughout the genome.

Exome sequencing measures DNA sequence, not gene expression. It therefore cannot directly establish whether a gene is expressed or how its RNA is spliced in a particular tissue; RNA sequencing can provide complementary evidence.

Comparison with other sequencing approaches

Approach Principal scope Main distinction from WES
Targeted gene panel A selected set of genes or regions Can offer deeper or more thoroughly validated coverage for a defined question, but has a narrower scope
Whole-exome sequencing Most annotated protein-coding regions, with assay-dependent additions Broad coding-region analysis with relatively limited sequencing requirements
[[whole-genome-sequencing Whole-genome sequencing]] Coding and noncoding genomic DNA
RNA sequencing RNA molecules present in a sample Examines expression and transcript structure rather than genomic sequence directly

A “virtual panel” may be applied to exome data by restricting initial analysis to selected genes. This limits interpretation rather than changing the regions originally captured and sequenced.

Technical and interpretive limitations

Incomplete capture and difficult genomic regions. Regions with extreme base composition, repetitive sequence, or close similarity to other genes can be poorly covered or incorrectly mapped. Some medically important genes contain such regions.

Limited noncoding analysis. Most deep intronic and regulatory variants lie outside standard exome targets. Capturing short exon boundaries does not provide comprehensive coverage of sequences involved in regulation or splicing.

Incomplete detection of complex variation. Repeat expansions, balanced rearrangements, many structural variants, and some exon-level deletions or duplications are not reliably detected by conventional WES. Mitochondrial DNA analysis also depends on the assay and cannot be assumed to be comprehensive.

Sensitivity to mosaicism and sample choice. A variant present in only a small proportion of cells may be missed. A variant confined to a particular tissue may not be present in the sampled material.

Knowledge-dependent interpretation. Disease-gene catalogs, population datasets, and classification evidence change over time. Reanalysis can produce new findings without generating new sequence data, although it cannot recover regions that were never adequately sequenced.

Uneven population representation. Underrepresentation of some ancestry groups in reference datasets can make rare variants harder to interpret and contribute to differences in rates of uncertain findings.

Laboratories may use complementary methods to investigate findings that are technically uncertain or outside the assay's validated capabilities.

Development and ethical considerations

WES developed from advances in massively parallel sequencing and targeted DNA enrichment during the late 2000s. It became an important bridge between sequencing individual genes and analyzing entire genomes, particularly for discovering causes of rare inherited disorders. Its relative advantages continue to depend on sequencing costs, laboratory infrastructure, analytical requirements, and the clinical or research question.

Because exome data cover many genes, analysis can reveal findings unrelated to the original reason for testing. Secondary findings generally refer to deliberately sought results outside that original question, whereas incidental findings arise unexpectedly; terminology and reporting practices vary.

Consent and reporting policies address which findings are analyzed or returned, testing involving children, storage and reuse of data, and information relevant to biological relatives. Genomic data also raise data privacy concerns because they are potentially identifiable and contain information shared with family members.